Provided by Tiger Trade Technology Pte. Ltd.

Aquestive Therapeutics Inc.

4.11
+0.27007.03%
Pre-market: 4.110.00000.00%04:00 EST
Volume:2.94M
Turnover:11.97M
Market Cap:501.43M
PE:-5.91
High:4.18
Open:3.91
Low:3.88
Close:3.84
52wk High:7.55
52wk Low:2.12
Shares:122.00M
Float Shares:115.00M
Volume Ratio:0.18
T/O Rate:2.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6953
EPS(LYR):-0.5089
ROE:148.50%
ROA:-25.50%
PB:-122.03
PE(LYR):-8.08

Loading ...

NASD Most Active Issues

Dow Jones
·
Feb 03

What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment?

Benzinga_recent_news
·
Feb 03

Leerink sees ‘silver lining’ in Aquestive CRL given defined path to approval

TIPRANKS
·
Feb 02

Aquestive CRL from FDA ‘clearing event,’ says Oppenheimer

TIPRANKS
·
Feb 02

Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Artivion (AORT)

TIPRANKS
·
Feb 02

Aquestive Therapeutics Shares Gain 38.6%

THOMSON REUTERS
·
Feb 02

Aquestive Therapeutics Shares Gain 35% Premarket

THOMSON REUTERS
·
Feb 02

BRIEF-Aquestive Therapeutics Announces FDA Issuance Of Complete Response Letter For Anaphylm

Reuters
·
Feb 02

Aquestive's Application for Allergic Reaction Treatment Has Deficiencies, FDA Says

Dow Jones
·
Feb 02

US FDA declines to approve Aquestive's oral drug for allergic reactions

Reuters
·
Feb 02

Aquestive Therapeutics Inc: Plans to Request Rapid Review by FDA

THOMSON REUTERS
·
Feb 02

Aquestive Therapeutics Inc - Deficiencies Limited to Packaging and Administration

THOMSON REUTERS
·
Feb 02

Aquestive Therapeutics Inc - Company Expects to Resubmit as Early as Q3 2026

THOMSON REUTERS
·
Feb 02

Aquestive Therapeutics Inc - Plans to Submit in Canada and EU by End of 2026

THOMSON REUTERS
·
Feb 02

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

GlobeNewswire
·
Feb 02

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM

Reuters
·
Feb 02

NASD Most Active Issues

Dow Jones
·
Jan 13

Aquestive Therapeutics Inc : Leerink Partners Cuts Target Price to $7 From $11

THOMSON REUTERS
·
Jan 12

Aquestive Therapeutics (AQST) Is Down 39.4% After FDA Flags Deficiencies in Anaphylm Filing - What's Changed

Simply Wall St.
·
Jan 12

Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet

Benzinga_recent_news
·
Jan 10